Amitabh Chandra, PhD, Ethel Zimmerman Wiener professor of public policy and director of health policy research at the Harvard Kennedy School of Government, says that while price regulation is not impossible, “It’s very, very hard to do. Given that it’s hard to do, do we need to do it?”
Earlier this year, Peter Bach, MD, and coauthors published an argument in Health Affairs in which they argued that biosimilar competition is an inefficient way to achieve the goal of lower prices for drugs and that the US government should instead regulate the prices of off-patent originator biologics.
That proposal led to dueling editorials from Bach’s camp—who write that it’s “time to throw in the towel” on biosimilars—and those who prefer to see a better set of conditions for competition in the US biosimilars market. Dissenters include Alex Brill, MA, and Benedic Ippolito, PhD, of the American Enterprise Institute (AEI), who shot back at Bach in their own Health Affairs blog, as well as former FDA Commissioner Scott Gottlieb, MD (who now also works with AEI), who argued in the Wall Street Journal that Congress “can make straightforward changes” that would help biosimilars to thrive.
Those changes could include, writes Gottlieb, mandating that innovator drug developers make samples available for testing, blocking rebates that “squelch” competition from biosimilars, and investing in more biosimilar education.
As the war of words between Bach and his critics shows little evidence of abating, The Center for Biosimilars® spoke to an expert in health economics—Amitabh Chandra, PhD, Ethel Zimmerman Wiener professor of public policy and director of health policy research at the Harvard Kennedy School of Government—about how feasible it would be to implement Bach’s proposal to regulate biologic drug prices rather than to continue to invest in the biosimilars market.
According to Chandra, “The key issue here is, if you were to regulate the price, how would you do it? We’re not very good at knowing how to regulate prices in this industry for a drug where the exclusivity period has run out.”
One issue in understanding how to regulate biologics’ prices would be the collection of a vast quantity of data on manufacturing costs for biologic medicines in order to reimburse drug makers on the basis of those costs. That could create a perverse incentive, says Chandra, to pad manufacturing costs: “We might end up paying more than we actually need to pay them.”
On the other hand, fear of overpayment could lead to paying drug makers too little, and “then we’ll get a raft of shortages.”
On a broader level, Chandra points out that US experience with regulating public utilities has not been altogether successful. “You can see that all the time with the postal service, with the railroads. Every time we try to do it, it’s not particularly clear that we do a good job.”
He adds that, in the healthcare sector, where Medicare sets prices for some services, “there’s a strong sense that those rates are not the right rates.” If price regulation fails in such areas of the healthcare system, “I’m not sure we’re going to be able to do it for a single manufacturer whose exclusivity period has expired. They might just leave the business completely.”
According to Chandra, while price regulation is not impossible, “It’s very, very hard to do. Given that it’s hard to do, do we need to do it?” The biosimilar market in the United States does not appear to be as dismal as Bach and colleagues have made it out to be, says Chandra. “If you look at something like Neupogen…volume of Neupogen is down about 50% as a result of biosimilar entry…maybe we would like it to fall more, which is the side that I’m on, but it’s not like it isn’t falling. It’s falling quite a bit.”
In terms of what he sees as needs in the biosimilars space, Chandra says that we cannot expect biosimilars to succeed purely by relying on market forces, and in that sense, Bach and colleagues “are on to something really important.”
We will need more regulation to help the industry to flourish, he said, and agreed with Gottlieb that better access to samples for testing would help expedite biosimilar market entry. He called sample availability one example of an area where the United States would benefit from increased regulation, and added that “the FDA could be of great assistance there.”
“My own sense of this is that we need more regulation to increase and expedite their entry. We do not need regulation that goes as far as price regulation.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.